NCT03647839 - Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 6, 2018

Primary Completion Date

January 29, 2021

Study Completion Date

April 9, 2021

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG

Nivolumab 10 MG/ML

Nivolumab will be supplied free of charge by Bristol-Myers Squibb (BMS) as sterile liquid in 10mL glass vials.

DRUG

BNC 105

BNC105 will be provided free of charge by Bionomics, as a sterile solution of BNC105P. BNC105P is a clear, colorless to yellow liquid presented in a clear glass vial and is intended to be diluted with commercially available sterile 0.9% saline prior to IV administration.

DRUG

BBI608

BBI-608 will be supplied free of charge by Boston Biomedical as capsules.

Trial Locations (14)

2065

Northern Cancer Institute, St Leonards

2145

Westmead Hospital, Westmead

2640

Border Cancer Hospital, Albury

3021

Western Health, Saint Albans

3084

Olivia Newton-John Cancer Wellness and Research Centre, Heidelberg

3168

Monash Health, Clayton

4029

Royal Brisbane Hospital, Herston

5011

Queen Elizabeth Hospital, Woodville South

5037

Ashford Cancer Centre Research, Kurralta Park

5042

Flinders Medical Centre, Bedford Park

Unknown

Newcastle Private Hospital, Newcastle

Ballarat Health Service, Ballarat

Eastern Health, Box Hill

Peninsula Health/Frankston Hospital, Mornington Peninsula

All Listed Sponsors

lead

Australasian Gastro-Intestinal Trials Group

NETWORK